Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We're excited in the multiple myeloma that ...
The bispecific T-cell engager talquetamab (Talvey) has some distinct adverse events (AEs) compared with drugs of the same class that target B-cell maturation antigen (BCMA) in mul ...
Exploring nationwide trends in multiple myeloma (MM), autologous stem cell transplants (ASCTs), chimeric antigen receptor T-cell (CAR-T) therapy and coronavirus disease 2019 (COVID-19) in ...
Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, ...
The FDA on Wednesday granted accelerated approval to linvoseltamab (Lynozyfic) for relapsed or refractory multiple myeloma after at least four prior lines of therapy. A B-cell maturation antigen (BCMA ...
Findings published today in Nature Cancer from Charles Mullighan, MBBS (Hons), MSc, MD, deputy director of the St. Jude Comprehensive Cancer Center, Department of Pathology, and collaborators show ...
New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results